Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis
- PMID: 36268493
- PMCID: PMC9577186
- DOI: 10.1016/j.afos.2022.05.004
Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis
Abstract
Objectives: Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients.
Methods: We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received high-dose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression.
Results: Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877-0.942 P < 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838-0.913, P < 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780-0.866, P < 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension.
Conclusions: Higher MPR is associated with a lower vertebral fracture risk.
Keywords: Diphosphonates; Medication adherence; Osteoporosis.
© 2022 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Bisphosphonate Use and the Risk of Undergoing Total Knee Arthroplasty in Osteoporotic Patients with Osteoarthritis: A Nationwide Cohort Study in Taiwan.J Bone Joint Surg Am. 2017 Jun 7;99(11):938-946. doi: 10.2106/JBJS.16.00385. J Bone Joint Surg Am. 2017. PMID: 28590379
-
Alendronate medication possession ratio and the risk of second hip fracture: an 11-year population-based cohort study in Taiwan.Osteoporos Int. 2020 Aug;31(8):1555-1563. doi: 10.1007/s00198-020-05399-9. Epub 2020 Mar 27. Osteoporos Int. 2020. PMID: 32221674
-
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases.Mayo Clin Proc. 2006 Aug;81(8):1013-22. doi: 10.4065/81.8.1013. Mayo Clin Proc. 2006. PMID: 16901023
-
Real-world Adherence and Persistence with Bisphosphonate Therapy in Postmenopausal Women: A Systematic Review.Clin Ther. 2019 Aug;41(8):1576-1588. doi: 10.1016/j.clinthera.2019.05.001. Clin Ther. 2019. PMID: 31151814
-
A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.Osteoporos Int. 2019 Apr;30(4):705-720. doi: 10.1007/s00198-018-4791-3. Epub 2019 Jan 8. Osteoporos Int. 2019. PMID: 30623214 Free PMC article.
Cited by
-
Treatment adherence and risk of vertebral fracture.Osteoporos Sarcopenia. 2022 Dec;8(4):165. doi: 10.1016/j.afos.2022.11.002. Epub 2022 Dec 12. Osteoporos Sarcopenia. 2022. PMID: 36605169 Free PMC article. No abstract available.
-
Impact of Medication Adherence on Bone Mineral Density and Fracture Risk in Patients With Osteoporosis: A Systematic Review.Cureus. 2023 Jul 19;15(7):e42115. doi: 10.7759/cureus.42115. eCollection 2023 Jul. Cureus. 2023. PMID: 37602050 Free PMC article. Review.
-
Reply on "Treatment adherence and risk of vertebral fracture".Osteoporos Sarcopenia. 2022 Dec;8(4):166. doi: 10.1016/j.afos.2022.11.003. Epub 2022 Dec 12. Osteoporos Sarcopenia. 2022. PMID: 36605168 Free PMC article. No abstract available.
References
-
- Johnell O., Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int. 2005;16:S3–S7. - PubMed
-
- Harvey N.D.E., Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010;6:99–105. - PubMed
-
- Johnell O.K.J. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;2006:1726–1733. - PubMed
LinkOut - more resources
Full Text Sources